Pharmacological Modulation of the Psychiatric Risk Factor FKBP51 Alters Efficiency of Common Antidepressant Drugs

Balsevich, 2017, Stress-responsive FKBP51 regulates AKT2-AS160 signaling and metabolic function, Nat. Commun., 8, 1725, 10.1038/s41467-017-01783-y

Bardal, 2011, Chapter 23—Psychiatry, Applied Pharmacology, 418

Ben-Efraim, 2011, Gene-environment interactions between CRHR1 variants and physical assault in suicide attempts, Genes Brain Behav., 10, 663, 10.1111/j.1601-183x.2011.00703.x

Binder, 2008, Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults, JAMA, 299, 1291, 10.1001/jama.299.11.1291

Binder, 2004, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment, Nat. Genet., 36, 1319, 10.1038/ng1479

Burghardt, 2013, Acute and chronic effects of selective serotonin reuptake inhibitor treatment on fear conditioning: implications for underlying fear circuits, Neuroscience, 247, 253, 10.1016/j.neuroscience.2013.05.050

Can, 2012, The mouse forced swim test, J. Vis. Exp., 59, e3638, 10.3791/3638

Criado-Marrero, 2018, Hsp90 and FKBP51: complex regulators of psychiatric diseases, Philos. Trans. R. Soc. Lond. B Biol. Sci., 373, 20160532, 10.1098/rstb.2016.0532

de Kloet, 2005, Stress and the brain: from adaptation to disease, Nat. Rev. Neurosci., 6, 463, 10.1038/nrn1683

Einoch, 2017, The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia, Eur. Neuropsychopharmacol., 27, 470, 10.1016/j.euroneuro.2017.03.005

Ellsworth, 2013, FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder, Pharmacogenet. Genomics., 23, 156, 10.1097/fpc.0b013e32835dc133

Eskelund, 2017, Drugs with antidepressant properties affect tryptophan metabolites differently in rodent models with depression-like behavior, J. Neurochem., 142, 118, 10.1111/jnc.14043

Ferrari, 2013, Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010, PLoS Med., 10, e1001547, 10.1371/journal.pmed.1001547

Fries, 2017, The FKBP51 glucocorticoid receptor co-chaperone: regulation, function and implications in health and disease, Int. J. Mol. Sci., 18, E2614, 10.3390/ijms18122614

Gaali, 2015, Selective inhibitors of the FK506-binding protein 51 by induced fit, Nat. Chem. Biol., 11, 33, 10.1038/nchembio.1699

Gassen, 2015, Chaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine, Sci. Signal., 8, ra119, 10.1126/scisignal.aac7695

Gassen, 2014, Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: evidence in cells, mice and humans, PLoS Med., 11, e1001755, 10.1371/journal.pmed.1001755

Hamilton, 2018, Protective role of FKBP51 in calcium entry-induced endothelial barrier disruption, Pulm. Circ., 8, 2045893217749987, 10.1177/2045893217749987

Hartmann, 2015, Pharmacological inhibition of the psychiatric risk factor FKBP51 has anxiolytic properties, J. Neurosci., 35, 9007, 10.1523/jneurosci.4024-14.2015

Hartmann, 2012, The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress, Neuropharmacology, 62, 332, 10.1016/j.neuropharm.2011.07.041

Hirschfeld, 1999, Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs, J. Clin. Psychiatry, 60, 326, 10.4088/jcp.v60n0511

Jakobsen, 2017, Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. a systematic review with meta-analysis and trial sequential analysis, BMC Psychiatry, 17, 58, 10.1186/s12888-016-1173-2

Kang, 2018, Longitudinal associations between glucocorticoid receptor methylation and late-life depression, Prog. Neuropsychopharmacol. Biol. Psychiatry, 84, 56, 10.1016/j.pnpbp.2018.02.004

Maiarù, 2018, The stress regulator Fkbp51: a novel and promising druggable target for the treatment of persistent pain states across sexes, Pain, 159, 1224, 10.1097/j.pain.0000000000001204

McIlwain, 2001, The use of behavioral test batteries: effects of training history, Physiol. Behav., 73, 705, 10.1016/s0031-9384(01)00528-5

Müller, 2003, Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress, Nat. Neurosci., 6, 1100, 10.1038/nn1123

Pariante, 2001, Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment, Biol. Psychiatry, 49, 391, 10.1016/s0006-3223(00)01088-x

Pratt, 2006, Chaperoning of glucocorticoid receptors, Handb. Exp. Pharmacol., 172, 111, 10.1007/3-540-29717-0_5

Rush, 2006, Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report, Am. J. Psychiatry, 163, 1905, 10.1176/appi.ajp.163.11.1905

Scharf, 2011, Expression and regulation of the Fkbp5 gene in the adult mouse brain, PLoS One, 6, e16883, 10.1371/journal.pone.0016883

Stonawski, 2018, Associations of prenatal depressive symptoms with DNA methylation of HPA axis-related genes and diurnal cortisol profiles in primary school-aged children, Dev. Psychopathol., 1, 10.1017/s0954579418000056

Strawn, 2018, Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review, Expert Opin. Pharmacother., 19, 1057, 10.1080/14656566.2018.1491966

Thase, 2006, Preventing relapse and recurrence of depression: a brief review of therapeutic options, CNS Spectr., 11, 12, 10.1017/s1092852900015212

Ulrich-Lai, 2009, Neural regulation of endocrine and autonomic stress responses, Nat. Rev. Neurosci., 10, 397, 10.1038/nrn2647